Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Council OKs Public Knowledge-Based Application for Diagnogreen, Valixa
December 26, 2017
- MHLW OKs Add’l Indications for Keytruda, Soliris and More
December 26, 2017
- Japan Cabinet OKs FY2018 Budget, 52.9 Billion Yen Earmarked for Urgent Drug Discovery Package
December 25, 2017
- “Comprehensive Strategy” Updated after 2 Years, MHLW to Mull Procedures for Info Handover for Brand-Name Meds Bowing Out of Market
December 25, 2017
- Single Price Band Rule for Generics to Get Underway in April 2020: MHLW
December 22, 2017
- Mogamulizumab Gets Orphan Status for HTLV-1-Associated Myelopathy
December 22, 2017
- Chuikyo Wraps Up CEA Debate for This Year, Sorts Out Issues towards Full Rollout
December 22, 2017
- 4th or Later Players Could Also Qualify for PMP If Post-Launch “True Clinical Utility” Premium Granted: MHLW
December 21, 2017
- Outline of Drug Pricing Reform Package
December 21, 2017
- Chuikyo OKs Drug Pricing Reform Package; 30% Cap Set for “Category I” Companies Allowed to Maintain Full Prices
December 21, 2017
- (Update) Japan to Shave 720 Billion Yen through FY2018 Drug Price Revision
December 19, 2017
- Meiji-Kumamoto JV Becomes “Company that Can Succeed Worldwide”: Kaketsuken Chief
December 19, 2017
- MHLW Approves Proposed Reforms to Allow the Export of Plasma Fraction Products
December 19, 2017
- Govt to Draw Up “Plan to Strengthen Drug Discovery,” Boosting Budgets to Improve R&D Environment
December 18, 2017
- Modified PMP Plan Reflects Some Industry Requests, but Not Sufficient: Chuikyo Pharma Rep
December 14, 2017
- Chuikyo Debate Intermitted as Members Fume at Political Arrangement, New PMP Plan Still Clears Panel with Strings Attached
December 14, 2017
- MHLW Plans to Establish Related Information Service for Improving Drug Distribution
December 14, 2017
- Chuikyo Members Snub Possible Change to 14-Day Prescription Limit
December 13, 2017
- LDP Lawmaker Prods MHLW to Include 4th or Later Drugs in PMP Coverage Too
December 13, 2017
- Japan and Taiwan to Conduct Pilot Project to Accelerate New Drug Reviews in Taiwan by Using PMDA’s Review Reports
December 13, 2017
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…